← All indications
Angina Pectoris
The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
Subtype terms (3)
More specific conditions that are subtypes of Angina Pectoris in the MeSH hierarchy.
- Angina, Stable
81 drugs (43 approved, 38 experimental)
- Angina, Unstable
55 drugs (38 approved, 17 experimental)
- Microvascular Angina
23 drugs (17 approved, 6 experimental)
Drugs by status
Approved for this indication (33)
- nitroglycerin
- candesartan
- chlorthalidone
- atenolol
- diltiazem
- amlodipine
- louxiangdan tongxin
- mibefradil
- Molsidomine
- nadolol
- atorvastatin
- propatylnitrate
- propranolol
- suxiao jiuxin
- ranolazine
- tongmai yangxin
- tongxinluo
- tribulus terrestris
- verapamil
- meldonium
- metoprolol
- hydrochlorothiazide
- gualou
- tetranitropentaerythritol
- oxprenolol
- sotalol
- isosorbide
- methafrone
- trolnitrate phosphate
- nicorandil
- +3 more
Phase 4 trials (32)
- heparin
- vitamin e
- cangrelor
- esmolol
- gliclazide
- musk
- rosuvastatin
- ivabradine
- icosapent ethyl
- pitavastatin
- vitamin c
- ticagrelor
- prasugrel
- pravastatin
- lidocaine
- alirocumab
- sitagliptin
- salvianolate
- sarpogrelate
- sirolimus
- acetylsalicylic acid
- everolimus
- testosterone
- carvedilol
- bivalirudin
- sildenafil
- pioglitazone
- regadenoson
- dobutamine
- sufonylurea
- +2 more
Phase 3 trials (14)
Phase 2 trials (24)
- omecamtiv mecarbil
- advvegf-d
- acetylcysteine
- caplacizumab
- liraglutide
- abciximab
- hemoglobin based oxygen carrier-201
- adenosine
- lacidipine
- peripheral blood lymphocytes
- febuxostat
- vericiguat
- allogeneic adipose derived mesenchymal stem cell
- biobypass
- umbilical cord mesenchymal stem cells
- autologous bone marrow derived mesenchymal cells
- pvgi.1 (vegf-2)
- selected cd 133+ cells
- autologous mesenchymal stem cells
- oxygen
- hydroxyethyl starch
- advegfxc1
- imb-1018972
- xc001
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (87)
- Takeda
- Forest Laboratories
- Gilead Sciences
- AstraZeneca
- Merck Serono
- Merck KGaA
- Ferozsons Laboratories Ltd.
- GlaxoSmithKline
- Green Valley Group of China
- IHF GmbH - Institut für Herzinfarktforschung
- JW Pharmaceutical
- Kobe University
- Mochida Pharmaceutical Company, Ltd.
- Shaanxi Buchang Pharmaceutical Co., Ltd
- Therabel Pharma SA/NV
- CardioVascular Research Foundation, Korea
- Fundação Educacional Serra dos Órgãos
- Burnasyan Federal Medical Biophysical Center
- University of Roma La Sapienza
- Region Syddanmark
- Huazhong University of Science and Technology
- Central South University
- Cardiovascular Consultants of Nevada
- Cedars-Sinai Medical Center
- China Academy of Chinese Medical Sciences
- Harvard University
- Emory University
- Federal University of Rio Grande do Sul
- Gachon University
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- +57 more
Organization Involved with Phase 3 Indications (32)
- Servier
- Centocor
- Sanofi
- Angionetics Inc.
- Baxalta
- Gene Biotherapeutics, Inc.
- Laboratórios Baldacci S.A
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
- Tasly Pharmaceuticals, Inc.
- Otsuka
- TSH Biopharm Corporation Limited
- Fondazione Mediolanum per Attività e Ricerche Cardiovascolari Onlus
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Heart, Lung, and Blood Institute (NHLBI)
- Northwestern University
- University of Pecs
- Urmia University of Medical Sciences
- University of Vermont
- Mayo Clinic
- Teikyo University
- University of Cincinnati
- National Taiwan University
- ATCGen
- Yangsan Busan University
- University of Montreal
- University of Sao Paulo
- Tianjin University
- University of Tuebingen
- Huapont Life Sciences
- Government of Brazil
- +2 more
Organization Involved with Phase 2 Indications (34)
- Ablynx
- Celgene
- Amgen
- Bayer
- Biopure Corporation
- CellPraxis Bioengenharia Ltda.
- Corautus Genetics
- Cryopraxis Criobiologia Ltda.
- GenVec
- Sinphar Pharmaceutical Co., Ltd
- Xintong Pharmacy Company
- Boehringer Ingelheim
- Cytokinetics
- North Florida Foundation for Research and Education
- University of London
- Radboud University
- University Hospital of North Norway
- University of South Florida
- University of Aberdeen
- Hunan University of Traditional Chinese Medicine
- Papworth Hospital NHS Foundation Trust
- Medical University of Vienna
- Tianjin Medical University
- Chengdu University of Traditional Chinese Medicines
- Kuopio University Hospital
- Department of Veteran Affairs
- FinVector Vision Therapies Oy
- Euram Limited
- Shandong University of Traditional Chinese Medicine
- Changchun University of Chinese Medicine
- +4 more
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (10)